Table 2

Cardiovascular study population and multidrug therapy

FactorCategoriesNon-CVD multidrug counts*†
Mean01–34–67 or more
Total study population162 (5.1)1220 (38.7)1316 (41.7)457 (14.5)
Age50–594.254 (10)257 (47.2)187 (34.7)41 (7.6)
60–694.862 (6.3)397 (40.3)397 (40.3)128 (13)
70–795.231 (2.8)404 (36.9)483 (44.1)177 (16.2)
80≥5.615 (2.8)162 (30.2)249 (46.4)111 (20.7)
GenderFemale5.358 (3.4)594 (34.8)757 (44.4)296 (17.4)
Male4.6104 (7.2)626 (43.2)559 (38.6)161 (11.1)
Deprivation quartiles†Q1—least deprived4.643 (5.6)351 (46)289 (37.9)80 (10.5)
Q24.945 (6.3)273 (38.4)294 (41.4)99 (13.9)
Q35.045 (5.4)321 (38.9)346 (41.9)114 (13.8)
Q4—most deprived5.529 (3.4)274 (32.1)387 (45.3)164 (19.2)
CVD groupsnon-HF CVD4.9161 (5.4)1176 (39.4)1235 (41.4)413 (13.8)
HF6.11 (.6)44 (25.9)81 (47.6)44 (25.9)
  • Figures in brackets are the percentage of each drug count category within each factor subgroup.

  • *Non-CVD multidrug counts = number of additional chapters (from 14 possible BNF chapters) from which at least one drug was prescribed over a 2-year time period (2000–2001).

  • Both CVD groups are defined by patients who received a British National Formulary Chapter 2 (CVD) drug prescription over a 2-year time period. Two mutually exclusive groups in the 2-year time-period (1) reference group = CVD drug and CVD diagnostic categories (other than HF) in the record review (2) HF group = CVD drugs and HF diagnostic categories.

  • †(n=3154).

  • BNF, British National Formulary; CVD, cardiovascular disease; HF, heart failure.